Jodi Eddy - Boston Scientific Senior Officer
| 0HOY Stock | 90.59 0.59 0.65% |
Executive
Jodi Eddy is Senior Officer of Boston Scientific Corp
| Age | 51 |
| Address | 300 Boston Scientific Way, Marlborough, MA, United States, 01752-1234 |
| Phone | 508 683 4000 |
| Web | https://www.bostonscientific.com |
Boston Scientific Management Efficiency
The company has return on total asset (ROA) of 0.049 % which means that it generated a profit of $0.049 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0892 %, meaning that it generated $0.0892 on every $100 dollars invested by stockholders. Boston Scientific's management efficiency ratios could be used to measure how well Boston Scientific manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Boston Scientific's Non Currrent Assets Other are comparatively stable compared to the past year. Other Assets is likely to gain to about 5.5 B in 2024, whereas Non Current Assets Total are likely to drop slightly above 21.4 B in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| SirpaHelena LLM | Uniper SE | 65 | |
| FCA FCA | Mulberry Group PLC | 75 | |
| Fabienne Twelemann | Uniper SE | N/A | |
| David Brown | SURETRACK MON | N/A | |
| Christopher Delbrck | Uniper SE | 58 | |
| Ulf Klostermann | Uniper SE | N/A | |
| Sebastian Veit | Uniper SE | N/A | |
| Stefan Jost | Uniper SE | N/A | |
| Kane Black | Ikigai Ventures | N/A | |
| Graham Crocker | Heavitree Brewery | 66 | |
| Risto MSc | Uniper SE | 56 | |
| Nicolo Prien | Uniper SE | 58 | |
| Andrea Baldo | Mulberry Group PLC | 52 | |
| Tina Bradshaw | Uniper SE | N/A | |
| Sascha Fehlemann | Uniper SE | 46 | |
| Klaus Schaeffer | Uniper SE | 57 | |
| Richard ACA | London Security Plc | 61 | |
| Niek Hollander | Uniper SE | N/A | |
| Carsten Poppinga | Uniper SE | N/A | |
| Katherine LLB | Mulberry Group PLC | N/A | |
| Nicola McLean | Heavitree Brewery | N/A | |
Management Performance
| Return On Equity | 0.0892 | ||||
| Return On Asset | 0.049 |
Boston Scientific Corp Leadership Team
Elected by the shareholders, the Boston Scientific's board of directors comprises two types of representatives: Boston Scientific inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Boston. The board's role is to monitor Boston Scientific's management team and ensure that shareholders' interests are well served. Boston Scientific's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Boston Scientific's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jodi Eddy, Senior Officer | ||
| Catherine Jennings, VP Interventions | ||
| John Sorenson, Executive Operations | ||
| Arthur Butcher, Executive Pacific | ||
| Michael Mahoney, President Chairman | ||
| Emily Woodworth, Global VP | ||
| Daniel CPA, Executive CFO | ||
| Vance Brown, General VP | ||
| Joseph Fitzgerald, Executive Cardiology | ||
| Mary Moynihan, Senior Officer | ||
| Daniel Brennan, Executive CFO | ||
| Jeffrey Mirviss, Executive Interventions | ||
| Jonathan Monson, Senior Relations | ||
| Susan Lisa, Vice Relations | ||
| David Roux, Independent Director | ||
| Jeffrey MBA, Executive Interventions |
Boston Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Boston Scientific a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0892 | ||||
| Return On Asset | 0.049 | ||||
| Profit Margin | 0.11 % | ||||
| Operating Margin | 0.17 % | ||||
| Current Valuation | 142.62 B | ||||
| Shares Outstanding | 1.38 B | ||||
| Shares Owned By Insiders | 0.17 % | ||||
| Shares Owned By Institutions | 92.44 % | ||||
| Price To Sales | 7.90 X | ||||
| Revenue | 14.24 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Boston Stock Analysis
When running Boston Scientific's price analysis, check to measure Boston Scientific's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Boston Scientific is operating at the current time. Most of Boston Scientific's value examination focuses on studying past and present price action to predict the probability of Boston Scientific's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Boston Scientific's price. Additionally, you may evaluate how the addition of Boston Scientific to your portfolios can decrease your overall portfolio volatility.